Amphastar Pharmaceuticals Stock Plummets to New 52-Week Low of $19.83

Amphastar Pharmaceuticals, Inc. has reached a new 52-week low, trading at USD 19.83 as of February 27, 2026. This marks a significant decline for the small-cap company, which operates within the Pharmaceuticals and Biotechnology industry. Over the past year, Amphastar has experienced a notable decrease in its stock price, with a performance drop of 51.42%, contrasting sharply with the S&P 500's gain of 17.36% during the same period. The company's market capitalization stands at USD 1,541 million, and it currently has a price-to-earnings (P/E) ratio of 9.00. Amphastar's financial metrics reveal a debt-to-equity ratio of 0.44 and a return on equity of 14.12%. Additionally, the stock has a price-to-book ratio of 1.98, indicating its valuation relative to its net assets. Despite these metrics, the stock's performance has been below par, contributing to its current position in the market. Investors and market observers will be closely monitoring any developments that may impact Amphastar's trajectory moving forward.